#1 Clinical Trials Search in Europe

Promethazine Hydrochloride

Promethazine Hydrochloride, a versatile medication, has been the subject of several clinical trials to evaluate its efficacy in treating various conditions. This article explores the use of Promethazine Hydrochloride in clinical studies, focusing on its applications in allergy treatment, migraine management, and vertigo relief. We’ll examine the drug’s effectiveness, dosage forms, and potential combinations with other medications to provide a comprehensive overview of its role in modern medicine.

Table of Contents

What is Promethazine Hydrochloride?

Promethazine Hydrochloride is a versatile medication that belongs to a class of drugs called antihistamines. It’s also known by several brand names, including Phenergan[1]. This medication has been used for various medical purposes for over 50 years[2].

Medical Uses of Promethazine

Promethazine Hydrochloride is used to treat several conditions:

  • Allergies: It’s effective in managing symptoms of allergic rhinitis, which is inflammation of the nasal passages due to allergies[3].
  • Nausea and Vomiting: Promethazine is commonly used to prevent and treat nausea and vomiting, especially after surgery (known as postoperative nausea and vomiting or PONV)[2].
  • Motion Sickness: It can help alleviate symptoms of motion sickness[1].
  • Sleeplessness: Due to its sedative effects, it’s sometimes used to treat occasional sleeplessness[4].
  • Vertigo: Some studies have explored its use in treating vertigo, which is a sensation of spinning or dizziness[5].

How Promethazine Works

Promethazine works by blocking the action of histamine, a substance in the body that causes allergic symptoms. It also affects other chemicals in the brain, which contributes to its anti-nausea and sedative effects[1].

Dosage and Administration

Promethazine comes in various forms and dosages, including:

  • Tablets
  • Liquid (elixir)
  • Injectable form for intramuscular (IM) use

The dosage varies depending on the condition being treated and the patient’s age. For example:

  • For allergies: Doses may range from 12.5 mg to 25 mg[3].
  • For nausea and vomiting: Doses as low as 3 mg to 6.25 mg have been studied for postoperative nausea and vomiting[2].
  • For sleeplessness: A 50 mg dose has been studied[4].

Always follow your doctor’s instructions or the directions on the label. Never increase your dose without consulting your healthcare provider.

Potential Side Effects

Like all medications, promethazine can cause side effects. The most common side effect is sedation or drowsiness[2]. Other potential side effects may include:

  • Dizziness
  • Dry mouth
  • Blurred vision
  • Constipation

In rare cases, more serious side effects can occur. If you experience any unusual symptoms, contact your healthcare provider immediately.

Ongoing Research

Researchers continue to study promethazine for various uses:

  • A study is comparing the effectiveness of promethazine with other medications (metoclopramide and prochlorperazine) in treating vertigo[5].
  • Another study is investigating the use of low-dose promethazine (3 mg) as part of a multi-drug approach to prevent postoperative nausea and vomiting in patients undergoing gynecological laparoscopic procedures[2].

These ongoing studies may provide more information about the optimal use of promethazine in various medical conditions.

Aspect Details
Primary Uses in Trials Allergy treatment, migraine management, vertigo relief
Dosage Forms Tablets, capsules, liquid formulations
Dosage Strengths 12.5 mg, 18.75 mg, 25 mg, 37.5 mg, 50 mg
Combination Therapies Studied with sumatriptan for migraines, compared with metoclopramide and prochlorperazine for vertigo
Primary Outcomes Measured Symptom relief, bioequivalence, pharmacokinetics
Safety Assessments Adverse events monitoring, vital signs, tolerability

FAQ

  • What is Promethazine Hydrochloride used for in clinical trials? Promethazine Hydrochloride has been studied in clinical trials for various uses, including the treatment of allergies, migraine-associated nausea and vomiting, and vertigo. It's often evaluated alone or in combination with other medications to assess its effectiveness in managing these conditions.
  • How is Promethazine Hydrochloride administered in clinical studies? In clinical trials, Promethazine Hydrochloride has been administered in various forms, including tablets, capsules, and liquid formulations. The dosage and administration method may vary depending on the specific study and condition being treated.
  • Are there any combination therapies involving Promethazine Hydrochloride being studied? Yes, some clinical trials have explored combination therapies involving Promethazine Hydrochloride. For example, one study investigated a combination of sumatriptan and Promethazine for treating acute migraine pain and associated symptoms.
  • What are some of the primary outcomes measured in Promethazine Hydrochloride trials? Clinical trials involving Promethazine Hydrochloride often measure outcomes such as relief from allergy symptoms, reduction in migraine-associated nausea and vomiting, improvement in vertigo symptoms, and overall safety and tolerability of the medication.
  • How does Promethazine Hydrochloride compare to other medications in clinical trials? Some clinical trials have compared Promethazine Hydrochloride to other medications or placebo. For instance, in vertigo treatment, it has been studied alongside medications like metoclopramide and prochlorperazine to assess its relative efficacy in managing symptoms.

Ongoing Clinical Trials on Promethazine Hydrochloride

  • Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Austria Croatia Denmark France Germany Greece +6

  • Study on the Effects of Promethazine on Coordination in Healthy Volunteers During Altered Gravity Conditions

    Not recruiting

    3 1 1
    Investigated drugs:
    France

  • Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France The Netherlands

  • Study on the Safety and Effectiveness of ALLO-501A and ALLO-647 for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

  • Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Germany

Glossary

  • Bioequivalence: The property of two drug products having the same active ingredient, dosage form, strength, and route of administration to be pharmaceutically equivalent and to have the same rate and extent of absorption when administered under similar conditions.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, used to assess bioequivalence and drug absorption.
  • Cmax: The maximum concentration of a drug in the blood after administration, used to evaluate the rate of drug absorption.
  • Tmax: The time it takes for a drug to reach its maximum concentration in the blood after administration.
  • Vertigo: A sensation of spinning or dizziness, often caused by problems in the inner ear or brain.
  • Migraine: A type of headache characterized by severe pain, often accompanied by nausea, vomiting, and sensitivity to light and sound.
  • Allergic Rhinitis: Inflammation of the nasal passages caused by an allergic reaction, resulting in symptoms such as sneezing, runny nose, and congestion.

References

  1. https://clinicaltrials.gov/study/NCT00947063
  2. https://clinicaltrials.gov/study/NCT01159548
  3. https://clinicaltrials.gov/study/NCT00762749
  4. https://clinicaltrials.gov/study/NCT02578186
  5. https://clinicaltrials.gov/study/NCT05586763